These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
102 related articles for article (PubMed ID: 30130546)
21. Is pre-treatment testosterone a prognostic factor in prostate cancer? Akumabor PN Cent Afr J Med; 1993 Aug; 39(8):170-2. PubMed ID: 8020082 [TBL] [Abstract][Full Text] [Related]
22. Low Serum Testosterone But Not Obesity Predicts High Gleason Score at Biopsy Diagnosed as Prostate Cancer in Patients with Serum PSA Lower than 20 ng/ml. Shiota M; Takeuchi A; Sugimoto M; Dejima T; Kashiwagi E; Kiyoshima K; Inokuchi J; Tatsugami K; Yokomizo A Anticancer Res; 2015 Nov; 35(11):6137-45. PubMed ID: 26504040 [TBL] [Abstract][Full Text] [Related]
23. Effect of copulation on potentially precancerous prostate lesions, serum testosterone and prolactin levels in rats. Herrera-Covarrubias D; Tecamachaltzi-Silvaran MB; Barradas-Moctezuma M; Rosales-Raya JB; Manzo J; García LI; Aranda-Abreu GE; Ismail N; Coria-Avila GA; Hernández ME Exp Oncol; 2016 Jun; 38(2):73-9. PubMed ID: 27356573 [TBL] [Abstract][Full Text] [Related]
24. Association between prostate cancer and serum testosterone levels. Zhang PL; Rosen S; Veeramachaneni R; Kao J; DeWolf WC; Bubley G Prostate; 2002 Nov; 53(3):179-82. PubMed ID: 12386917 [TBL] [Abstract][Full Text] [Related]
25. Serum testosterone as a biomarker for second prostatic biopsy in men with negative first biopsy for prostatic cancer and PSA>4ng/mL, or with PIN biopsy result. Fiamegos A; Varkarakis J; Kontraros M; Karagiannis A; Chrisofos M; Barbalias D; Deliveliotis C Int Braz J Urol; 2016; 42(5):925-931. PubMed ID: 27532110 [TBL] [Abstract][Full Text] [Related]
26. A new era of testosterone and prostate cancer: from physiology to clinical implications. Khera M; Crawford D; Morales A; Salonia A; Morgentaler A Eur Urol; 2014 Jan; 65(1):115-23. PubMed ID: 24011426 [TBL] [Abstract][Full Text] [Related]
27. Re: Masashi Yano, Takashi Imamoto, Hiroyoshi Suzuki et Al. The clinical potential of pretreatment serum testosterone level to improve the efficiency of prostate cancer screening. Eur urol 2007;51:375-80. Morgentaler A Eur Urol; 2007 Jul; 52(1):292; author reply 293-4. PubMed ID: 17400361 [No Abstract] [Full Text] [Related]
30. Investigative clinical study on prostate cancer part IV: exploring functional relationships of total testosterone predicting free testosterone and total prostate-specific antigen in operated prostate cancer patients. Porcaro AB; Petrozziello A; Migliorini F; Lacola V; Romano M; Sava T; Ghimenton C; Caruso B; Zecchini Antoniolli S; Rubilotta E; Monaco C; Comunale L Urol Int; 2011; 86(4):399-406. PubMed ID: 21508618 [TBL] [Abstract][Full Text] [Related]
31. Serum testosterone and the risk of prostate cancer: potential implications for testosterone therapy. Parsons JK; Carter HB; Platz EA; Wright EJ; Landis P; Metter EJ Cancer Epidemiol Biomarkers Prev; 2005 Sep; 14(9):2257-60. PubMed ID: 16172240 [TBL] [Abstract][Full Text] [Related]
32. Effect of orchidectomy on serum concentrations of testosterone and dihydrotestosterone in patients with prostatic cancer. Røhl HF; Beuke HP Scand J Urol Nephrol; 1992; 26(1):11-4. PubMed ID: 1631501 [TBL] [Abstract][Full Text] [Related]
33. [Morphological and hormonal diagnosis of prostate cancer]. Minkov N; Kumanov Kh; Tsvetkov M; Topov Ia; Maleeva A Khirurgiia (Sofiia); 1983; 36(3):249-51. PubMed ID: 6198553 [No Abstract] [Full Text] [Related]
34. Re: effect of finasteride on serum levels of androstenedione, testosterone and their 5α-reduced metabolites in men at risk for prostate cancer. Traish AM; Morgentaler A J Steroid Biochem Mol Biol; 2013 Nov; 138():462. PubMed ID: 23851167 [No Abstract] [Full Text] [Related]
35. The relationship between total and free serum testosterone and the risk of prostate cancer and tumour aggressiveness. Faydaci G; Kuyumcuoglu U BJU Int; 2010 Jan; 105(2):281; author reply 281. PubMed ID: 20078600 [No Abstract] [Full Text] [Related]
36. Behavior of total and free serum testosterone as a predictor for the risk of prostate cancer and its aggressiveness. Regis L; Planas J; Celma A; de Torres IM; Ferrer R; Morote J Actas Urol Esp; 2015 Nov; 39(9):573-81. PubMed ID: 25944770 [TBL] [Abstract][Full Text] [Related]
37. Serum measurements of testosterone, insulin-like growth factor 1, and insulin-like growth factor binding protein-3 in the diagnosis of prostate cancer among Korean men. Hong SK; Han BK; Jeong JS; Jeong SJ; Moon KH; Byun SS; Lee SE Asian J Androl; 2008 Mar; 10(2):207-13. PubMed ID: 18097534 [TBL] [Abstract][Full Text] [Related]
38. Does baseline total testosterone improve the yielding of prostate cancer screening? Botelho F; Pina F; Figueiredo L; Cruz F; Lunet N Eur J Cancer; 2012 Jul; 48(11):1657-63. PubMed ID: 22342552 [TBL] [Abstract][Full Text] [Related]
39. Higher sex hormone-binding globulin and lower bioavailable testosterone are related to prostate cancer detection on prostate biopsy. García-Cruz E; Carrión Puig A; García-Larrosa A; Sallent A; Castañeda-Argáiz R; Piqueras M; Ribal MJ; Leibar-Tamayo A; Romero-Otero J; Alcaraz A Scand J Urol; 2013 Aug; 47(4):282-9. PubMed ID: 23181478 [TBL] [Abstract][Full Text] [Related]
40. Low testosterone levels are related to poor prognosis factors in men with prostate cancer prior to treatment. Morgentaler A BJU Int; 2012 Dec; 110(11 Pt B):E547. PubMed ID: 22583384 [No Abstract] [Full Text] [Related] [Previous] [Next] [New Search]